Purdue Pharma: Innovative Healthcare Solutions

Eisai and Purdue Pharma Announce Positive Topline Results of SUNRISE 2,
the Second Phase 3 Pivotal Study of Lemborexant

Oct 17, 2018

Long-term efficacy and safety evaluation in patients with insomnia, a sleep-wake disorder, met primary and key secondary efficacy ... Read more

Purdue Pharma Urges Accuracy in Communications
on Abuse-Deterrent Formulations of Opioids

Sep 24, 2018

STAMFORD, Conn. – September 24, 2018 – Marcelo E. Bigal MD, Ph.D. Chief Medical Officer, Purdue Pharma L.P., issued the ... Read more

Purdue Pharma L.P. to Present Data from Three Research Studies at
PAINWeek^® 2018 Annual Conference

Sep 6, 2018

Studies Underscore Company’s Ongoing Commitment to Working Collaboratively on Meaningful Solutions to Address the Opioid Crisis STAMFORD, Conn., ... Read more

Purdue Pharma L.P. and Geisinger Present Interim Analysis from
Wearable Health Technology Clinical Trial at PAINWeek^® 2018 Annual Conference

Sep 6, 2018

Results Show Successful Uptake of Technology and Increased Patient-Provider Communication STAMFORD, Conn., and DANVILLE, Pa. – September 6, ... Read more

Purdue Pharma L.P. to Fund Harm Reduction Therapeutics, Inc.’s Work to Develop Inexpensive,
Over-the-Counter, Life-Saving Naloxone in the United States

Sep 5, 2018

STAMFORD, Conn. and PITTSBURGH, Penn., September 5, 2018 – Purdue Pharma L.P. (Purdue) and Harm Reduction Therapeutics, Inc. today announced ... Read more

Purdue Pharma L.P. and Research Collaborators to Present Data at PAINWeek^® 2018 Annual Conference

Aug 28, 2018

Posters Include Interim Data from Wearable Health Technology Study and Research Initiatives to Evaluate Prescription Drug Monitoring, Take ... Read more

Prescription Drug Safety Curriculum Increased Student Knowledge by 49
Percent in its Inaugural Academic Year

Aug 15, 2018

Purdue Expands Established Commitment to Include a Statewide Education Program in Collaboration with EVERFI and Connecticut Prevention Network ... Read more

Purdue Pharma L.P. Advances Its Pipeline with Novel, Potential First-in-Class Small Molecule for Insomnia Associated with Alcohol Cessation

Jul 31, 2018

STAMFORD, Conn., July 31, 2018 – Purdue Pharma L.P. today announced completion of a Phase 1b dose-ranging study of a ... Read more

Purdue Pharma L.P. Announces Leadership Changes

Jul 24, 2018

Company Names Steve Miller Chairman of the Board of Directors and Marc Kesselman Senior Vice President and General ... Read more

Eisai and Purdue Pharma Announce Oral Presentation of Latest Clinical and Non-Clinical Data on Lemborexant at 43rd Annual Meeting of the Japanese Society of Sleep Research

Jul 2, 2018

Presentation includes data from first-ever Phase 3 head-to-head superiority comparison vs zolpidem ER in patients with a sleep-wake ... Read more

More news

Recent News